Cullinan Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nadim Ahmed
- Full Time Employees
- 111
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- One Main Street Cambridge MA United States of America 02142
- IPO Date
- Jan 8, 2021
- CIK
- 0001789972
- Website
- cullinantherapeutics.com
- Similar Companies
- Business
- Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing modality-agnostic targeted therapies for autoimmune diseases and cancer. The company’s product portfolio includes clinical-stage molecules such as CLN-619, CLN-978, zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617, which are designed to inhibit key drivers of disease or leverage the immune system to eliminate diseased cells. Zipalertinib, developed in collaboration with Taiho Oncology, Inc., targets genetically defined subsets of non-small cell lung cancer; CLN-049 is a novel FLT3xCD3 bispecific T cell engager for relapsed/refractory acute myeloid leukemia and recently received FDA Fast Track designation. Cullinan therapeutics also pursues CLN-978 specifically for autoimmune diseases, with systemic lupus erythematosus as a primary indication, reflecting a strategic expansion from oncology into immunology. The company operates primarily in the United States and through partnerships internationally, including Taiho Pharmaceutical in Greater China for commercialization outside the U.S. and China. Founded in 2016 and headquartered in Cambridge, Massachusetts, Cullinan recently changed its name from Cullinan Oncology to reflect its broadened autoimmune disease focus. Recent major developments include the initiation of a rolling submission for zipalertinib’s New Drug Application to the U.S. FDA, discontinuation of enrollment in its B-NHL study to focus on autoimmune diseases, a strategic partnership with Taiho Pharmaceutical for global commercialization rights of CLN-081/TAS6417, and financial positioning with cash resources supporting operations into 2029. The company emphasizes advancing first- or best-in-class therapies through clinical trials for high unmet medical needs in both autoimmune and oncologic therapeutic areas.
Cullinan Therapeutics: Heading Toward Paydirt
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases Transcript
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
The Biology Came First.
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cullinan Therapeutics (NASDAQ:CGEM) versus Genprex (NASDAQ:GNPX) Head to Head Comparison
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference
Nadim Ahmed Sells 16,381 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock
Jennifer Michaelson Sells 11,742 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist
Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript